Companies

Trevor Martin talked to In Vivo about the importance of sharing a strategic vision with partners, the company’s superpower, and how a PhD is the best prep for a startup.

New product launches come with great expectations, which are sometimes unrealistic. This can lead to disappointment. Lately, market access restrictions are exacerbating sales challenges.

Dealmakers from CAR-T biotech Poseida Therapeutics and Astellas recently sat down with In Vivo to discuss how they reached a $600m deal that combines their technologies and how they plan on moving forward.

Fusion Pharmaceuticals Inc CEO John Valliant talked to In Vivo about Canadian leadership in radiopharmaceutical innovation, its differentiated approach, and excitement around combination therapies for precision cancer treatments.

The Swiss company is aiming to regain its innovator status and expand its offering across all breast cancer settings. Approval of Itovebi is just the start.

CRN/Radicle Trailblazing Woman Award to ChromaDex’s Yasmeen Nkrumah-Elie; Nourish’s TV ad campaign features US soccer star Alex Morgan; Vitamin Shoppe BodyTech Elite Altered Strength line sponsors Team Red, White & Blues; contract pharma/consumer health product development firm LabConnect appoints Wesley Wheeler CEO; Avanos’ Game Ready is “Recovery Partner” of NFL’s Nick Bosa; Akita adds Robert Hanson to advisory board; and BODi has wrestler as brand ambassador

The payout will bring GSK closer to resolving lawsuits which have occupied it for years – though investors are now likely to focus on new product growth concerns at the UK firm.

UK pharma also reaches agreement in principle, subject to DoJ approval, to pay $70m to resolve a whistleblower complaint filed by Valisure, the testing lab which in 2019 raised concerns about a potential link between the use of drugs containing ranitidine, a histamine-2 blocker, and cancer.

Arexvy has become the first RSV vaccine to show it can provide protection over three years – but that might mean lower market uptake than originally expected.

But biotechs are still having to price their offerings lower than they had planned.